Reperfusion Injury

BALTIMORE, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a leader in the field of non-degrading molecular glues, is pleased to announce the upcoming presentation of preclinical in vivo data from its selective ENT1 inhibitor for Acute Kidney Injury (AKI) at the American Society for Nephrology (ASN) Kidney Week 2024 to be held from October 24-27, 2024, in San Diego, CA. Rapafusyn’s lead program, RAP-0001, is advancing rapidly to address a critical unmet need: the prevention of Acute Kidney Injury (AKI) in patients undergoing cardiac surgery. AKI is a severe and common complication, leading to prolonged hospital stays, increased morbidity, and higher mortality rates. With no approved therapies currently available, novel solutions are urgently needed. RAP-0001, a potent and selective inhibitor of the ENT1 transporter, has shown preclinical efficacy in preventing ischemia/reperfusion injury, a major driver of AKI. “This compound was discovered through the RapaGlue™ platform. As a molecular glue, RAP-0001 uniquely binds to the intracellular chaperone protein FKBP12 and ENT1 to form a ternary complex. To our knowledge, it’s the only SLC inhibitor that targets the intracellular domain of a transporter,” said Dr. Matthew Olson, VP of Biological Sciences of Rapafusyn, who will present in vivo data demonstrating RAP-0001’s ability to significantly reduce kidney damage in this high-risk context on October 25 th , 2024. Dr. Sean Hu, CEO of Rapafusyn, stated, “We believe RAP-0001 could change the standard of care for AKI, providing a critical therapeutic option where none currently exist. This is yet another example of recent developments demonstrating how non-degrading molecular glues could potentially tackle challenging disease targets and address high unmet medical needs in ways more effective than other drug modalities.” About Rapafusyn At Rapafusyn, we’re creating non-degrading molecular glues to address hard-to-drug targets. Using our FKBP12-binding macrocyclic peptide platform, we’ve built large DNA encoded libraries (DELs) and arrayed libraries, yielding novel starting points. Our approach targets intracellular proteins and domains of transmembrane proteins like SLCs, ion channels, and GPCRs. With a modular design, we rapidly optimize key drug properties to accelerate drug-discovery. For more information, please visit or contact Heather Lavin at hlavin@rapafusyn.com .

2025 commercial launch planned to expand access to this platform technologyOXFORD, England and MADISON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) -- OrganOx Ltd, a world-leading organ medical technology company, today announced Health Canada has approved the OrganOx metra® System for use during liver transplantation. The OrganOx metra® System is currently commercially available for liver transplantation in the U.S., the U.K., and the European Union. The company plans to commercially launch the system in Canada in 2025. The OrganOx metra® System utilizes normothermic machine perfusion, or NMP, to circulate oxygenated blood, medications, and nutrients to donated organs at normal body temperature and near physiological conditions. This innovative technology extends organ preservation time, allows pre-transplant clinical assessment of organ viability and can dramatically improve operational logistics for both transplant teams and patients.1 “We are thrilled to receive this authorization in Canada, further advancing our vision to improve clinical outcomes for liver transplant patients around the globe,” said Craig Marshall, CEO of OrganOx. “In the coming months we look forward to introducing the metra® to transplant centers across Canada.” The performance of the metra® system has been evaluated across several clinical trials including the Consortium for Organ Preservation in Europe (COPE) European Trial, the first randomized trial to assess machine perfusion versus static cold storage in liver transplantation. Compared with static cold storage, the OrganOx metra® achieved a 50% lower level of graft injury despite a 54% longer mean preservation time.2 About OrganOxOrganOx is a commercial stage organ technology company with a focus on the preservation of isolated organs, spun out of the University of Oxford in 2008. The company’s first product, the OrganOx metra® normothermic machine perfusion (NMP) system for the liver, has been used to support more than 4,000 liver transplant operations globally, optimizing the use of donated organs by enabling assessment of the quality of livers as well as longer preservation durations. Other applications, including in kidney transplantation, are in development. Learn more at www.organox.com. About OrganOx metra®OrganOx metra® is a fully automated NMP device that enables continuous monitoring and evaluation of the liver, empowering surgeons to make evidence-based decisions on whether to transplant a donor organ and enabling viability testing.1 metra® is commercially available in UK (UKCA: 772261), European Union (CE Mark: MDR 772263 and MDR 772678) and the United States (FDA Approved: P200035). ContactsInvestor Relations:Steve DeitschChief Financial Officer, OrganOxinvestorrelations@organox.com Media:Emma YangHealth+Commerceemma@healthandcommerce.com References: Watson, C.J.E, Gaurav, R., Fear, C. et al. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation 106(12): 2391–2398 (2022) https://doi.org/10.1097/TP.0000000000004263Nasralla, D., Coussios, C.C., Mergental, H. et al. A randomized trial of normothermic preservation in liver transplantation. Nature 557, 50–56 (2018). https://doi.org/10.1038/s41586-018-0047-9

Non-dilutive $7.45M Phase III SBIR Temporary Vascular Occlusion Clamp (TVOC) contract to commercialize innovative technology targeting hemorrhage control for the U.S. Air Force. CAMBRIDGE, Mass., Oct. 2, 2024 /PRNewswire/ -- Amsel Medical Corporation today announces that it has been awarded an $7.45 million sole source, non-dilutive, small business innovative research (SBIR) Phase III contract by the United States Air Force. This award represents a significant milestone for the company and builds on successful prior AFWERX Phase I, Phase II and TACFI SBIR contracts with the U.S. Air Force. This contract will help accelerate the commercialization of Amsel's breakthrough, SCureTO™, precision hemorrhage control solution for combat casualty care trauma. It is expected to provide a life and limb saving capability to the Department of the Air Force, Special Operations Command, and U.S. Department of Defense (DoD) in preparation for future "near peer" conflicts. Amsel's SCureTO™ device enables rapid, minimally invasive, needle delivered arterial clamping upstream of an injury, providing a solution for acute and prolonged hemorrhage control in the field that is especially beneficial for non-compressible junctional injuries. The emergency responder can adjust the degree of vessel occlusion and distal perfusion, minimizing the potential consequences of prolonged limb ischemia and "reperfusion injury", and most importantly extends the "golden hour" for safe evacuation. When no longer required, the clamp can be removed without supplemental surgical or interventional procedures. Hemorrhage due to trauma is the leading preventable cause of death in the military setting, accounting for up to 90% of potentially preventable deaths. In the civilian setting, it is the second highest cause of death in trauma patients. James A. Heinz, CEO, Amsel Medical commented, "The military and civilian hemorrhage fatalities occur in the prehospital environment. As a result, there is a critical need for a device that is minimally invasive and deployable in the field to help prevent blood loss and aid in the urgent care of those wounded. For prolonged field care or longer transport, there is a need to "convert" tourniquets in a timely manner that can help save a limb and reduce amputations. This is core to Amsel's mission – "Saving Limbs and Saving Lives" for both those who serve, and to serve the broader public's need for improved trauma care." Additionally, "On a personal note, it gives me great pride in our team's ability to not only develop the technology, but to execute on previous Phase I and II milestones that led to this announcement." Colonel (ret) John Dorsch who served most recently as the U.S. Air Force's 24th Special Operations Wing surgeon general, stated, "This initiative will provide a novel solution to control junctional hemorrhage not amenable to application of an external tourniquet. Its ability to rapidly and effectively control non-compressible and junctional hemorrhage non-surgically will be critical in the future operating environment." About Amsel Medical Corporation Amsel Medical Corporation is a medical device company, based in Cambridge, Massachusetts, delivering simple and secure precision clamping technologies for vessel and tubular structure occlusion through commercialization of a temporary trauma solution (SCureTO™) and a permanent implant (SCureClamp™). For more information, please visit or contact [email protected]. CONTACT: Chris Gale at [email protected] SOURCE Amsel Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED